Willard, Melinda D.
Eli Lilly (United States)
3 papers on CoChatORCID 0000-0002-2937-962X
Most cited papers
- Verified
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
Heist, R. S., Koyama, T., Murciano-Goroff, Y. R., Hollebecque, A., Cassier, P. A., Han, J.-Y., Tosi, D., Sacher, A. G., Burns, T. F., Spira, A. I., et al. (2024) · Journal of Clinical Oncology
Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations
Cited by 48
- Verified
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Murciano-Goroff, Y. R., Heist, R. S., Kuboki, Y., Koyama, T., Ammakkanavar, N. R., Hollebecque, A., Patnaik, A., Shimizu, T., Spira, A. I., Nagasaka, M., et al. (2023) · Cancer Research
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 40
- Verified
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications
Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free